CeriBell, Inc. (CBLL) News & EventsCBLLCeriBell, Inc.

Ceribell Receives FDA Clearance for New Software to Accelerate EEG Interpretation

CeriBell announced that the U.S. Food and Drug Administration, FDA, has cleared new software for the Ceribell System that "makes it easier and faster" for clinicians to interpret longitudinal brain activity and make appropriate clinical decisions. "In critical care, time is brain, and every hour spent waiting for interpretation of EEG is time lost delivering treatment at the bedside," said Jane Chao, Ph.D., co-founder and CEO of Ceribell. "We expect to integrate these new features through an automatic software update in the first half of 2027."

Company Updates Outlook, Expects Revenue Growth of 28%-31%

Consensus $114M. The updated outlook represents growth of approximately 28% to 31% over the company's prior year revenue. This reflects continued momentum in its core business, driven by both new account additions and increased utilization within its established account base. "Combined with the early progress of our delirium pilot and multiple new FDA 510(k) clearances, we are highly confident in the strength of our business and our mission to establish EEG as a new vital sign," said CEO Jane Chao.

Company Reports Q2 Revenue of $28.1M, Beating Expectations

Reports Q2 revenue $28.1M, consensus $27.28M. Total revenue increased 33% year-over-year, driven primarily by continued growth in new account additions and increased utilization within existing accounts. "Our second quarter results reflect adoption accelerating across both new and existing accounts," said co-founder and CEO Jane Chao.